Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Barbara, Gerhardt"'
Autor:
Maekawa Michihide, Ryosuke Koretomo, Sudhakar M. Pai, Seiji Enya, Barbara Gerhardt, Tomohiro Ishikawa, Hiromasa Tanaka, Hiroyuki Yamada, Jeffrey Connaire
Publikováno v:
Clinical Pharmacology in Drug Development. 9:728-741
The mass balance, pharmacokinetics, and biotransformation of JTZ-951 (enarodustat), a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, were characterized in patients (N = 6) with end-stage renal disease on hemodialysis. Following a 10-mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0083e55fecc7c89c32991b87022fd0b
https://doi.org/10.1002/cpdd.752
https://doi.org/10.1002/cpdd.752
Autor:
Sudhakar M, Pai, Jeffrey, Connaire, Hiroyuki, Yamada, Seiji, Enya, Barbara, Gerhardt, Michihide, Maekawa, Hiromasa, Tanaka, Ryosuke, Koretomo, Tomohiro, Ishikawa
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(6)
The mass balance, pharmacokinetics, and biotransformation of JTZ-951 (enarodustat), a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, were characterized in patients (N = 6) with end-stage renal disease on hemodialysis. Following a 10-mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d927ba050536095f63818da98d196d0
https://pubmed.ncbi.nlm.nih.gov/31876104
https://pubmed.ncbi.nlm.nih.gov/31876104
Autor:
Hiroyuki Yamada, Sudhakar M. Pai, Tsutomu Shibata, Thomas L. Hunt, Sekihiro Tamaki, Barbara Gerhardt
Publikováno v:
Clinical pharmacology in drug development. 8(3)
Pharmacokinetics, safety, and tolerability of JTK-853, a novel HCV polymerase inhibitor, were evaluated in single and multiple ascending dose (SAD, MAD) studies, with food- and ketoconazole-related effects on exposure to JTK-853 and its active (CYP3A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60b4214c81d2752a5b2006da78cb3586
https://pubmed.ncbi.nlm.nih.gov/30779479
https://pubmed.ncbi.nlm.nih.gov/30779479
Autor:
Kunihiro Hirahara, Gabriela Turcanu, Toru Noguchi, Barbara Gerhardt, Yukiyo Toyonaga, Sudhakar M. Pai, Kan Yee, Maribel Rodriguez-Torres, Tsutomu Shibata, Naoki Ogura, Izuru Ando
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:436-444
JTK-853, a palm site-binding NS5B nonnucleoside polymerase inhibitor, shows antiviral activity in vitro and in hepatitis C virus (HCV)-infected patients. Here, we report the results of genotypic and phenotypic analyses of resistant variants in 24 HCV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce043270d63d4b0f9f57e5f0974c227
https://doi.org/10.1128/aac.01432-12
https://doi.org/10.1128/aac.01432-12